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Differences in Peripheral Noradrenergic Function among 
Actively Drinking and Abstinent Alcohol‐dependent 
Individuals 
We examined whether excessive alcohol consumption was related to changes in plasma levels of 
noradrenaline (NA) and whether these changes recover following abstinence. We also explored 
whether there were differences in NA levels between Type I and Type II alcoholics and controls 
during active drinking and abstinence. Plasma concentrations of NA were determined in (1) 27 
Caucasian men with alcohol dependence who were regularly drinking (active drinkers) within 24 
hours of hospitalization, (2) 29 Caucasian alcohol‐dependent men who were in remission 
(abstinent for a minimum of three months), and (3) 28 race‐ and gender‐matched healthy 
controls. NA concentrations were significantly higher in actively drinking alcohol‐dependent 
subjects compared to those in remission and controls. While Type I and Type II alcoholic 
individuals differed across clinical measures, NA levels were similar in the two subtypes. Both 
subtypes showed an elevation in NA levels during active drinking compared to controls, but NA 
levels did not differ between the two subtypes and controls during remission. The findings 
indicate that chronic exposure to alcohol may lead to disturbances in NA activity that may 
manifest in early abstinence. However, the changes in NA activity appears to normalize after a 
longer period of abstinence. Alterations in NA activity do not seem to be specific for Type I or 
Type II subtypes of alcoholism. 
Several lines of evidence support the involvement of the central noradrenergic (NA) system in 
mediating the behavioral effects of alcohol (ethanol). For example, animal experiments have 
shown that acute alcohol exposure increases NA synthesis and release, leading to increased NA 
concentrations in the brain.1-3 The sedative, intoxicating, and locomotor effects of alcohol, as 
well as alcohol withdrawal, seem to be related at least in part to increased NA activity.4-6 
Studies have also found that the central NA system may contribute to the rewarding effects of 
ethanol via its interaction with the dopaminergic pathways.7 Further support for the role of NA 
in mediating the effects of alcohol comes from genetic knock‐out experiments. Weinshenker et 
al.8 showed that mice lacking NA had a markedly reduced preference for ethanol and were 
hypersensitive to the sedative and hypothermic effects of ethanol.  
Compared to the preclinical evidence supporting the effects of alcohol on NA function, there 
have been several inconsistencies in human data that have limited the interpretation of findings. 
The conflicting findings appear to be related to the pharmacokinetics of alcohol metabolism and 
several clinical variables that are difficult to control among humans. For example, alcohol's 
effects on NA seem to vary with dose, length of exposure, and stage of withdrawal. While a 
number of studies have replicated findings of increased NA activity during early withdrawal,9, 
12 data during intoxication and abstinence have been less consistent. While subsensitive alpha‐2 
adrenergic receptor function has been reported in alcoholics following extended abstinence in 
some studies,13 other studies could not replicate the findings.14 Similarly, measurements of 
cerebrospinal fluid levels of monoamines in recently detoxified alcoholic patients15 could not 
confirm previous reports of alterations in neuroendocrine responsivity of the NA system that 
were observed in similar patients.16 Moreover, the effects of acute ethanol administration have 
been often studied in healthy subjects17-19 that bear little resemblance to clinical populations of 
alcoholic individuals.  
Biological studies in alcohol dependence are further complicated by the heterogeneity of the 
clinical population.20 Studies of problem drinkers and their families have yielded two broad 
categories, termed Type I and Type II by Cloninger21 and Type A and Type B by Babor et al.22 
The Type II alcoholism is predominantly limited to men and represented by an earlier age of 
onset of alcohol problems, greater severity of problems, stronger familial and genetic influences, 
and higher impulsivity and violent behavior. In contrast, the Type I subgroup is more benign 
with a later onset, higher anxiety levels, slower developmental course, fewer complications, and 
a better prognosis. Biological studies have found the two subtypes may differ in measures of 
serotonin,23 dopamine,24 and monoamine oxidase activity.25 Very few studies of the 
noradrenergic system during different stages of alcohol dependence have taken into account the 
distinct subgroups of alcoholic individuals.  
In an earlier study that investigated serotonergic function in alcohol dependence, we found that 
Type II alcoholism was associated with increased platelet tritiated imipramine binding that 
persisted during abstinence.26 In the present study, that work is extended to examine the role of 
NA system in alcoholism. The primary objective was to examine the differences in peripheral 
NA levels in alcohol‐dependent individuals during active drinking and abstinence. The 
secondary objective was to determine if the Type I and Type II subgroups of alcoholic patients 
differ from each other and from controls in measures of NA function.  
METHODS 
Recruitment 
The sample comprised of three groups of male, Caucasian individuals: 
• 1  
27 alcohol‐dependent inpatients who were still drinking. 
• 2  
29 alcohol‐dependent subjects who were in remission (abstinent for a minimum of three 
months, termed “abstinent alcoholics”). 
• 3  
28 healthy volunteers with no history of alcohol dependence or abuse, serving as the 
control population. 
Over 90% of the clinical population from which the sample was drawn was of Caucasian 
background. We restricted the population to men because Type II alcoholism is predominately 
male‐limited; also, significant variations of urinary NA have been reported in women.27 
The actively drinking alcohol‐dependent subjects were recruited from a university‐affiliated 
inpatient addiction unit in Nottingham, England. The inclusion criteria were: 
• 1  
DSM‐IV diagnosis of alcohol dependence.28 
• 2  
No interruption of alcohol intake in the previous 72 hours and no clinical evidence of 
alcohol withdrawal. 
• 3  
Capable of giving informed consent. 
Individuals with major depression, bipolar or psychotic disorders, serious medical disorders, or a 
positive urine drug screen (except benzodiazepines), as well as those receiving psychotropic 
medication (except benzodiazepines), were excluded from the study. Alcohol‐dependent subjects 
were recruited, and blood samples were obtained within 24 hours of admission to the inpatient 
unit. 
Abstinent alcoholics were recruited from a residential recovery house in Nottingham. Complete 
abstinence was mandated for residing in the recovery house, and attendance at Alcoholics 
Anonymous (AA) was encouraged. Most of the residents were in treatment at the outpatient 
clinic or day hospital affiliated with the addiction unit and underwent random breath tests. 
Subjects who were previously dependent on alcohol (DSM‐IV) but currently abstinent for at least 
three months were included in the study. The exclusion criteria were similar to those for the 
actively drinking group.  
Controls were hospital employees or their relatives. They were excluded if they had a positive 
response to items on the CAGE questionnaire, had a positive breathalyzer reading, reported 
greater than 21 units of alcohol consumption per week in the previous month (one unit is 
equivalent to 10 ml or 8 g of pure alcohol and corresponds to 4 fluid ounces of table wine, 1.5 
fluid ounces of spirits, or 8 fluid ounces of beer), had a major psychiatric or medical disorder, or 
were receiving psychotropic medication. 
Behavioral and Clinical Assessments 
The study protocol was approved by the ethics committee of the hospital. After a description of 
the study, written informed consent was obtained. Alcohol‐dependent individuals who 
volunteered for the study underwent a psychiatric interview and had their medical health 
assessed by medical history and physical examination. Alcohol history was recorded in a 
standardized format. Eligible subjects were asked to provide a urine sample and tested for breath 
alcohol levels. Subjects then completed a battery of psychological assessments that included the 
severity of alcohol dependence questionnaire (SADQ),29 a visual analogue scale for craving 
(VAS),30 and a questionnaire to classify subjects into Type I and Type II subtypes of 
alcoholism.21 
The SADQ is a 20‐item, self‐report questionnaire that assesses severity of alcohol dependence 
and requires about 20 minutes to complete. The items assess five functional areas: physical 
problems, emotional problems, pattern of drinking, amount of drinking, and withdrawal 
symptoms. For each item, the scores range from 0 (mild) to 3 (severe), so the total score can 
range from 0–60. The reliability and validity of the instrument have been established in studies 
of alcoholic patients from United Kingdom.29 
The VAS has been frequently used to quantify craving for drugs and alcohol and has been used 
as a subjective measure of alcohol craving.30 It can be completed in two minutes. Subjects were 
asked to rate their craving on a 100 mm horizontal line, and the distance from the left end of the 
line was measured in mm to provide an estimate of craving. The scores ranged from 0 (no 
craving) to 100.  
The Type I/Type II classification was based on procedures outlined by Gilligan et al.31 and 
Sullivan et al.32 The questionnaire included 12 variables that were categorized as representing a 
Type I characteristic (eg, first dependence or abuse symptom after age 25) or a Type II 
characteristic (eg, family history of alcoholism). All positive responses to Type I items (ie, yes) 
were weighted positively (+) and all positive responses to Type II items were weighted 
negatively (—). A total score was obtained for each subject by summing scores for all items. 
Subjects with scores in the positive range were classified as Type I; individuals with negative 
scores received a Type II classification. A score of 0 was considered to represent “unclassified” 
grouping. The questionnaire required 10–15 minutes to complete.  
Consenting controls were screened using the CAGE questionnaire,33 a clinical interview, a 
physical examination, and breath alcohol readings. The CAGE is a four‐item questionnaire that 
takes about a minute to complete. It has been extensively employed as a screening tool to detect 
alcoholism in clinical settings. A positive response to one or more of the four questions has been 
found to be highly correlated with a diagnosis of alcoholism with a sensitivity of 84% and 
specificity of 90%.34 
The NA Assay 
Twenty ml of venous blood was collected from subjects and controls. For hospitalized, alcoholic 
subjects, blood was drawn within 24 hours of admission. The average time period from the time 
of admission to the time of blood collection was 7.4 hours. Blood samples were collected in the 
morning and transported to the laboratory on ice within two hours of blood draw to reduce the 
possibility of platelet aggregation. The samples were centrifuged within four hours of arrival at 
the laboratory to separate the plasma from the blood constituents. The plasma was separated and 
stored at — 80 C. In the laboratory, all samples were identified by code numbers and assayed as 
a single experiment to minimize variations in the plasma NA levels. The NA assay was 
performed using High Performance Liquid Chromatography (HPLC) with electrochemical 
detection optimized for the detection of NA. Details of the techniques for the NA assay have 
been previously described.35-37 The protein assay was performed by the methods described by 
Lowry et al.38 The NA concentrations were expressed in picomoles/mg of protein. The 
laboratory personnel were kept blind to the clinical data.  
Blood samples from alcoholic subjects were also analyzed for serum Gamma Glutamyl 
Transpeptidase (GGT) and Mean Corpuscular Volume (MCV) values. Both elevated GGT and 
MCV are indicative of excessive alcohol consumption and reported to be elevated in 50–75% of 
alcoholic individuals.39 
Statistical Analysis 
Analysis of variance (ANOVA) or independent t‐tests (two‐tailed) were employed to compare 
the three study groups and the Type I and Type II subgroups with respect to NA levels and 
scores on the clinical variables. Chi‐square tests were used to compare dichotomous variables. 
Relationships between clinical variables and NA levels were examined using Pearson or point 
biserial correlations. When significant relationships were observed between NA levels and 
clinical measures, the data were reanalyzed using analyses of covariance (ANCOVA) to control 
for the effects of other dependent variables on NA. 
RESULTS 
Subjects 
A total of 84 Caucasian men were studied: 27 were actively drinking, alcohol‐dependent 
patients, 29 were alcohol‐dependent individuals in remission (abstinent alcoholics), and 28 were 
healthy volunteers. Table 1 summarizes the demographic and clinical characteristics of the 
sample.  
Table 1. Clinical Characteristics of Subjects and Controls  
Characteristics 
Actively drinking (n 
= 27) 
Abstinent (n = 
29) 
Controls (n = 
28) 
F/t/χ2 
Age (years) 39.4 ± 10.1 41.1 ± 9.4 36.6 ± 6.4 F = 1.69 
Employed 27.5% 32.1% 93.1% 
χ2 = 
14.22†  
Single 68.9% 75.0% 44.8% 
χ2 = 
8.26*  
Duration of problem drinking 
(years) 
19.2 ± 10.4 20.4 ± 12.7 N/A t = 1.18 
Severity of drinking (SADQ 
scores) 
41.4 ± 10.6 46.5 ± 9.9 N/A t = 1.32 
Craving (VAS scores) 54.2 ± 32.1 29.6 ± 19.7 N/A t = 2.50* 
MCV‡ 96 ± 6 91 ± 9 N/A t = 1.38 
GGT § 249 ± 507 48 ± 42 N/A t = 3.61† 
Benzodiazepines ¶ 35.7% 28.3% N/A χ2 = 1.18  
Characteristics 
Actively drinking (n 
= 27) 
Abstinent (n = 
29) 
Controls (n = 
28) 
F/t/χ2 
Tobacco smokers 89.6% 92.8% 34.4% 
χ2 = 
11.31†  
• * p < .05, for t tests df = 54, for χ2 df = 1–2.  
• † p < .01, for t tests df = 54, for χ2 df = 1–2.  
• ‡ Normal MCV values ranged from 76–97 fl.  
• § Normal GGT values ranged from 10–50 IU/L.  
• ¶ Prescribed or present in the urine.  
As seen in Table 1, the three groups did not differ significantly in age; however, alcohol‐
dependent individuals were significantly more likely to be single, unemployed, and tobacco 
smokers than controls. While the actively drinking and abstinent patients did not differ in 
severity or duration of drinking, the former had higher craving scores and GGT levels than the 
latter group. Among patients who were actively drinking, the breath alcohol level was 121 ± 84 
mg, and two patients had alcoholic hepatitis. No individuals had tested positive for HIV; 
however, thirteen (23.2%) alcoholic individuals had a history of medical diseases such as liver 
disease, asthma, hypertension, or diabetes, or were taking medications for their medical 
conditions. Five actively drinking subjects were taking benzodiazepines (BZ); however, ten 
(35.7%) had evidence of recent use of BZ in urine. More than a quarter of abstinent individuals 
were prescribed BZ, and three were taking disulfiram. None of the alcoholics was prescribed 
more than 20 mg of diazepam (or its equivalents) a day.  
Plasma NA Levels in Alcoholic Individuals, Abstinent Alcoholics, and Controls 
For technical reasons, four blood samples could not be analyzed. The NA data are reported for 
eighty individuals. The plasma NA levels significantly differed between actively drinking 
individuals (5.08 ± 2.32), abstinent patients (3.15 ± 1.94), and controls (3.03 ± 1.31) (F [2, 78] = 
10.12, p < .001). Data analysis showed that NA levels were significantly higher in actively 
drinking compared to abstinent persons and controls; the latter two groups had similar NA 
concentrations. Figure 1 shows the distribution of plasma NA concentrations in the three groups.  
 
Figure 1  
Open in figure viewerPowerPoint 
Plasma noradrenaline in active drinkers, controls, and abstinent alcoholics. 
Since there were demographic differences between the three groups, we examined whether these 
variables were related to plasma NA levels. We found that NA levels were not significantly 
correlated with employment, marital status, or smoking status (X2 ranged from 0.48 to 1.87, df = 
2, p > .05 in each case), or with GGT values, breath alcohol levels, craving scores (r ranged from 
.05 to .17, p > .05 in each case). We also compared NA levels between alcoholic individuals 
taking benzodiazepines and those who were not, and found no significant differences between 
the two groups (X2 = 2.11, df = 1, p > .05). We then assessed the influence of comorbid medical 
diseases (eg, hypertension, asthma) on NA levels in alcoholic individuals by comparing the NA 
levels between patients with concurrent medical disorders (n = 13) and those without such 
disorders (n = 43). No significant difference was found between the two groups = 1.87, df = 1, p 
> .05).  
We also examined the relationship between clinical variables (severity and duration of drinking, 
craving, and duration of abstinence) and plasma NA levels in alcoholic patients. A significant 
positive correlation was observed between NA levels and the total score (r = 0.38, p < .05) and 
scores on the quantity (r = 0.37, p < .05) and withdrawal sub‐scales (r = .35, p < .05) of the 
SADQ. However, duration of drinking or craving scores were not significantly correlated with 
NA concentrations. Among abstinent alcoholics, the duration of abstinence was 5.9 ± 3.3 
months. Two patients were abstinent more than twelve months, with the maximum duration 
being sixteen months. No significant correlation was observed between duration of abstinence 
and NA concentrations (r = .18, p > .05).  
NA Levels in Type I and Type II Alcoholics 
In the combined alcoholic sample, 23 individuals were classified as Type I, 28 as Type II, and 
five were rated as “unclassified”. While the two subtypes did not differ in demographics, Type II 
alcoholics were more likely to have a longer duration of drinking (t = 2.58, df = 49, p < .05), 
higher GGT values (t = 2.38, df = 49, p < .05), and higher scores on the physical problems 
subscale of the SADQ (t = 2.17, df = 47, p< .05). The other clinical variables did not differ 
between the two subtypes. Because the alcohol‐dependent group who were drinking regularly 
had higher NA levels than controls, we examined whether Type I (n = 12) and Type II (n = 13) 
individuals in this group differed in their NA levels. No significant differences in NA levels were 
observed between Type I (4.96 ± 1.98) and Type II (4.98 ± 2.73) individuals (t = .21, df = 23, p 
> .05). Since Type I and Type II individuals differed in certain SADQ measures and SADQ 
scores were related to NA levels, we reanalyzed the data covarying for SADQ scores. The 
ANCOVA analysis did not change the direction or significance of the findings.  
DISCUSSION 
NA Levels During Alcohol Dependence and Abstinence 
The present study found that plasma NA levels were significantly elevated in chronic alcohol‐
dependent men who were still drinking compared to those who were abstinent for at least three 
months and controls. Because blood samples in the alcohol‐dependent group were drawn at 
different time points and breath alcohol levels were variable, it is difficult to uniformly 
characterize the clinical and physiological status of this group. Although some patients clinically 
had signs of intoxication and blood samples were collected before clinical signs of withdrawal 
were evident, patients had stopped drinking over seven hours before the blood draw. Therefore, 
it seems that physiologically most patients were in an early asymptomatic abstinent state. The 
increase in NA levels observed in this state is consistent with the animal data regarding the 
effects of alcohol on the noradrenergic system.1, 2 The results also support previous studies in 
humans that found plasma catecholamines to be increased following alcohol exposure and 
withdrawal12, 40 and reports of down‐regulation of alpha‐2 receptors in recently detoxified 
alcoholic subjects.16, 41 However, contrasting findings have also been reported possibly related 
to differences in stages of alcohol dependence. For example, Ibsen et al.42 have also reported 
normal NA concentrations in chronic, stable alcoholics, though it was unclear in this study 
whether subjects were in early withdrawal. Contrary to our expectations, breath alcohol levels 
were not correlated with plasma NA levels in the actively drinking group. One reason could be 
that a single breath alcohol value does not indicate whether blood alcohol levels were stable, 
increasing, or declining in a particular individual. It is likely that a proportion of patients might 
have reduced their consumption before hospitalization and, although intoxicated, may actually 
have had declining blood alcohol levels. Another reason for the lack of correlation between NA 
and alcohol levels could be individual differences in the magnitude of physiological tolerance 
and dependence on alcohol. We also failed to find a relationship between NA levels and craving 
during active drinking and abstinence, supporting findings from a recent study that did not 
observe a relationship between levels of NA metabolites in cerebrospinal fluid cue‐induced 
craving in alcohol‐dependent subjects.15 It seems that dopaminergic and serotonergic 
mechanisms may be preferentially involved in mediating craving for drugs and alcohol along 
with cognitive, affective, and psychological factors.43, 44 
NA Levels in Type I and Type II Alcoholism 
As expected, the Type II alcoholics had a longer duration of drinking, more physical problems, 
and higher levels of GGT and also tended to drink more compared to the Type I group. After 
correcting for these clinical differences, NA levels were similar in Type I and type II alcoholics 
during active drinking and abstinence. While there is a large body of evidence that Type I and 
Type II alcoholics may differ in serotonergic23, 45 and dopaminergic24 function the data on 
differences in NA function between the two subtypes have been less robust. While early research 
indicated that there may be differences in platelet mono‐amine oxidase (MAO) activity between 
the two subtypes 21, 25 two genetic studies have yielded negative results.46, 47 Although there 
have been suggestions that the Type I alcoholics may have higher anxiety levels than the Type II 
subgroup our study did not find any differences in plasma NA between the two subtypes. 
However it is possible that although NA levels may have normalized within a few weeks of 
abstinence changes in adrenergic receptor function could persist for much longer periods.13 
Further research comparing adrenergic receptor function between the two subtypes during 
abstinence may clarify whether the two subtypes are characterized by differences in the 
noradrenergic system.  
Methodological Issues 
Given the variations in effects of alcohol on the NA metabolism selection of sample becomes 
critical in biological studies of alcoholics. Because our objective was to compare chronic 
alcohol‐dependent patients who were actively drinking with those who were abstinent we studied 
alcoholics before clinical withdrawal was evident and recruited subjects with elevated levels of 
alcohol in the breath. This also ensured that subjects were not started on detoxification regimens 
with large doses of benzodiazepines that can suppress NA activity.48 Similarly abstinence was 
determined by objective data controls were clinically screened and Type I and Type II 
classifications were obtained using standardized assessments. We also examined the effects of 
potential confounding variables such as duration and severity of drinking and the use of tobacco 
and concomitant benzodiazepines. Nevertheless the data have to be interpreted in light of certain 
limitations. First the stress of hospitalization itself may have increased the levels of NA in the 
actively drinking group. Because we did not measure other biochemical indices such as cortisol 
levels or NA metabolites it was not possible to distinguish between the effects of alcohol and 
stress of hospitalization in our subjects. However studies have shown that stress by itself cannot 
explain the increases in NA seen in hospitalized alcoholics.49 Also it is likely that both 
controls—who were unaccustomed to screening interviews, breath tests, and venepuncture—and 
recovering alcoholics—whose behavior was heavily regulated in the residential facilities—also 
experienced stress. Finally, the interaction between alcohol and stress is not necessarily 
synergistic but may also be antagonistic. For example, in experimental animals, alcohol given 
prior to immobilization (ie, stress) has been found to reduce the restraint‐induced elevations in 
NA.50 Given these circumstances, it seems that the over 60% increase in NA in the actively 
drinking alcoholics compared to the other two groups does not seem to be due to stress of 
hospitalization alone. Second, the extent to which plasma NA reflects changes in NA function in 
human brain is unclear. Certain metabolic differences are present between periphery and the 
brain in humans that may need to be considered during interpretation of data (eg, high‐affinity 
alcohol dehydrogenase enzyme is absent in the brain51). However, human studies have found 
correlations between brain and plasma levels of MHPG and NA, and plasma NA and its 
metabolites are believed to be a major determinant of levels of NA in the cerebrospinal fluid.52 
We also acknowledge that the small sample size may have affected the ability to detect 
hypothesized differences in NA levels between the Type I and Type II subtypes or the possible 
differences between alcoholics with high and low amounts of drinking. Finally, since the sample 
was restricted to Caucasian men to control for possible race and gender effects, the data cannot 
be generalized to women and to individuals from other ethnic backgrounds.  
Clinical Significance and Conclusions 
The increases in NA levels in alcohol‐dependent individuals who were actively drinking indicate 
that chronic exposure to alcohol may lead to disturbances in NA activity that may be manifested 
in early abstinence. The normalization of NA levels with a longer period of abstinence suggests 
that the alcohol‐induced NA changes may be state‐dependent phenomena. Although the Type I 
and Type II alcoholics differ clinically, NA measures do not appear to distinguish between the 
two subtypes. Determining the influence of selective NA agents on the central effects of alcohol 
as well as examining the relationships between NA and dopaminergic mechanisms during 
different stages of alcohol dependence may clarify the importance of the NA system in mediating 
the addictive properties of alcohol in humans. 
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